Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants-Reference-Cited by-同舟云学术

Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants

Published:2022-07-13 Issue:13 Volume:96 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Bi Wenwen¹²³,Chen Guilin¹²³,Dang Bobo¹²³^ORCID

Affiliation:

1. Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China

2. Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China

3. Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, China

Abstract

Peptides derived from the SARS-CoV-2 HR1 region are generally poor inhibitors. Here, we constructed a trimeric peptide HR1MFd by fusing the trimerization motif foldon to the C terminus of the HR1 peptide.

Funder

NSFC | NSFC-Zhejiang Joint Fund | 浙江省科学技术厅 | Basic Public Welfare Research Program of Zhejiang Province

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.00681-22

Reference30 articles.

1. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

2. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

3. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

4. A pneumonia outbreak associated with a new coronavirus of probable bat origin

5. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical development of antivirals against SARS-CoV-2 and its variants;Current Research in Microbial Sciences;2024

2. An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen;Emerging Microbes & Infections;2023-08-11

3. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines;Signal Transduction and Targeted Therapy;2023-05-10

4. Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus;Frontiers in Microbiology;2023-01-19

5. Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins;International Journal of Molecular Sciences;2022-12-07